Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | SD-101 plus pembrolizumab for HNSCC

Ezra Cohen • 19 Oct 2018
ESMO 2018
Head and Neck Cancer Pembrolizumab SD-101

Ezra Cohen, MD, FRCPSC, FASCO, of the UC San Diego Moores Cancer Center, San Diego, CA, discusses an exciting trial of SD-101, a TLR9 agonist that is given via intratumor injection, with pembrolizumab for head and neck squamous cell carcinoma (NCT02521870). The study investigated this combination in two groups: patients who had never received a PD-1 inhibitor before, and PD-1 refractory patients. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Ezra Cohen

3:13
PD-L1 and alternative biomarkers in head and neck cancer
Ezra Cohen • 16 Apr 2023
1:41
The future of liquid biopsies in head and neck cancer
Ezra Cohen • 16 Apr 2023
2:01
Petosemtamab has promising activity in advanced HNSCC
Ezra Cohen • 16 Apr 2023
1:37
Mono or combination immunotherapy for HNSCC?
Ezra Cohen • 26 Oct 2018

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals